All news

MCL remission duration doubles with rituximab

Added: Tuesday 2 August 2011

Elderly patients with mantle cell lymphoma (MCL) experienced doubled remission time when they received rituximab as maintenance therapy after responding to induction therapy.The randomised controlled trial involved 564 patients from eight different European countries.

+  http://www.medscape.com/viewarticle/744453?sssdmh=dm1.695145&src=nldne


//